The Diactive-1 project aims to establish the Diactive-1 mobile application as a clinical tool for managing type 1 diabetes in children and adolescents in several hospitals from Spain. The successful implementation of the app in new healthcare centers nationwide represents a key step toward the development of a comprehensive and scalable program. This approach seeks not only to optimize current patient care but also to democratize access to an innovative, evidence-based intervention that supports daily diabetes management. In this new phase, the project will integrate the application into routine clinical care for patients with type 1 diabetes through the use of a simple handgrip strength measurement. A dedicated web platform (www.diactive.es) is being developed to allow clinicians to enter basic patient data, including handgrip strength, sex, and email address. Based on this information, the system will automatically generate a personalized download link for the Diactive-1 app, accompanied by tailored guidance and an initial fitness level classification (low, medium, or high) according to European reference values. This process will define each user's baseline fitness level and facilitate the use of Diactive-1 as an integrated and individualized disease management tool. The ultimate goal is to strengthen clinical decision-making, improve patient engagement, and extend the benefits of digital health to a broader pediatric population living with type 1 diabetes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
158
Participants will engage in a 12-week resistance exercise program with the goal of maintaining at least 3 sessions per week, with 3-6 exercises per session (≈13-33 minutes). Participants will be able to choose among three training formats, traditional resistance training, Tabata/high-intensity intervals, or circuit training, and may perform the sessions individually or in pairs, depending on preference and feasibility at the center. The training intervention will comprise 3-4 sets of 6-12 repetitions and will consist of a combination of exercises for the upper body, lower body, and core, using primarily the participants' own body weight. The load and intensity of the exercise will be adjusted according to the number of repetitions and the difficulty/progression of the selected exercises. A mobile application (Diactive-1) will be used to deliver, monitor, and record the sessions.
Fundación Miguel Servet/ Navarrabiomed
Pamplona, Navarre, Spain
Change in handgrip strength
Handgrip strength measured in kilograms using the Takei III Smedley Type Digital Dynamometer
Time frame: Baseline and 12 weeks
Change in daily insulin dose requirement
The daily insulin dose requirements will be measured in units per kilogram of body weight. Assessment will rely on participant-reported data from insulin pumps or injection logs, gathered for 7 days prior to the intervention and after the intervention.
Time frame: Baseline and 12 weeks
Change in glycated hemoglobin
Glycated hemoglobin (measured in percent)
Time frame: Baseline and 12 weeks
Number of participants with good glycemic control
Number of participants with a glycated hemoglobin level lower than 7%
Time frame: Baseline and 12 weeks
Change in time in range
The percentage of time a person spends with their blood glucose levels in the target range (70-180 mg/dL or 3.9-10 mmol/L) (measured in percent)
Time frame: Baseline and 12 weeks
Change in time below range
The percentage of time a person spends with their blood glucose levels below the target range (\<70 mg/dL or \<3.9 mmol/L, i.e., hypoglycemia) (measured in percent)
Time frame: Baseline and 12 weeks
Change in time above range
The percentage of time a person spends with their blood glucose levels above the target range (\>180 mg/dL or 10 mmol/L, i.e., hyperglycemia) (measured in percent).
Time frame: Baseline and 12 weeks
Change in glycemic variability
Glycemic variability measures the fluctuation in blood glucose levels over time, expressed as a percentage. Lower glycemic variability indicates more stable levels, while higher glycemic variability suggests greater fluctuations.
Time frame: Baseline and 12 weeks
Change in compliance with 24-hour movement behaviors
Physical activity at different intensities (average min/day), sedentary time (average min/day) and sleep (average min/day) will be measured using self-reported questionnaires.
Time frame: Baseline and 12 weeks
Change in self-reported physical activity
Aerobic and muscle-strengthening activities will be assessed using two separate ad hoc questions. Participants will have response options ranging from 0 to 7 days per week, with increments of 1 day.
Time frame: Baseline and 12 weeks
Change in self-reported physical fitness
The International Fitness Scale (IFIS) will be used to assess self-reported physical fitness. This scale includes five elements that will employ a 5-point Likert scale to inquire about children's overall perception of their physical fitness, as well as their perception of their cardiorespiratory fitness, muscular fitness, speed-agility, and flexibility compared to their peers. The Likert scale will provide choices ranging from 'very poor' to 'poor,' 'average,' 'good,' and 'very good' physical fitness.
Time frame: Baseline and 12 weeks
Change in sleep duration
Sleep duration will be determined by recording the number of hours slept each day
Time frame: Baseline and 12 weeks
Change in physical literacy
Physical literacy will be assessed using the Spanish Perceived Physical Literacy Instrument (S-PPLI), a 9-item questionnaire that evaluates three dimensions: knowledge and understanding; self-expression and communication; and sense of self and self-confidence
Time frame: Baseline and 12 weeks
Change in physical activity barriers
We will use the Spanish adaptation of the Physical Activity Barriers Scale for pediatric type 1 diabetes (PABS-1), a validated instrument for assessing perceived barriers to physical activity in children and adolescents with type 1 diabetes
Time frame: Baseline and 12 weeks
Adherence to the Mediterranean Diet
For assessing adherence to the Mediterranean Diet, the KIDMED index will be employed. This index provides a score on a scale of 0 to 12, with higher scores indicating stronger adherence.
Time frame: Baseline and 12 weeks
Change in disordered eating
Disordered eating will be screened using the mSCOFF questionnaire. This questionnaire consists of six straightforward yes/no questions. A positive response to two or more of these questions suggests a potential eating disorder, often requiring further evaluation.
Time frame: Baseline and 12 weeks
Change in subjective well-being
Subjective well-being will be assessed using the CUBE questionnaire, which comprises five items that evaluate different aspects of life satisfaction and emotional states.
Time frame: Baseline and 12 weeks
Change in Health-Related Quality of Life
Health-Related Quality of Life will be evaluated using the Screening for and Promotion of Health-Related Quality of Life in Children and Adolescents (KIDSCREEN-10).
Time frame: Baseline and 12 weeks
Change in Health-Related Quality of Life in the context of a chronic illness
Health-Related Quality of Life in the context of a chronic illness will be evaluated using the Spanish version of the 'Questionnaire for Young People with Diabetes' (DISABKIDS).
Time frame: Baseline 12 weeks
Change in microalbuminuria
Microalbuminuria will be evaluated as an indicator of early kidney involvement. A first-morning urine sample will be collected, and the albumin-to-creatinine ratio (ACR) will be determined using standardized laboratory procedures. Values will be expressed in mg/g. Microalbuminuria will be defined as an ACR between 30 and 300 mg/g, according to international diabetes guidelines.
Time frame: Baseline and 12 weeks
Change in retinal findings
Retinal imaging will be performed to assess early signs of diabetic retinopathy. Images of both eyes will be captured following standard ophthalmologic protocols and evaluated by trained specialists. Findings will be categorized as no retinopathy, mild, moderate, or severe diabetic retinopathy, based on international classification criteria.
Time frame: Baseline and 12 weeks
Change in body mass index
Weight and height will be combined to report body mass index in kg/m\^2
Time frame: Baseline and 12 weeks
App usability: user
The usability of the app will be evaluated using the Spanish Version of the User Version of the Mobile Application Rating Scale (uMARS).
Time frame: 12 weeks
App usability: expert evaluation
We will employ the Spanish adaptation of the Mobile Application Rating Scale (MARS), a standardized instrument for expert appraisal of mHealth applications.
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.